<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Croat Med J</journal-id><journal-id journal-id-type="iso-abbrev">Croat. Med. J</journal-id><journal-id journal-id-type="pmc-domain-id">394</journal-id><journal-id journal-id-type="pmc-domain">croatmedj</journal-id><journal-id journal-id-type="publisher-id">CMJ</journal-id><journal-title-group><journal-title>Croatian Medical Journal</journal-title></journal-title-group><issn pub-type="ppub">0353-9504</issn><issn pub-type="epub">1332-8166</issn><publisher><publisher-name>Medicinska Naklada</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC6330771</article-id><article-id pub-id-type="pmcid-ver">PMC6330771.1</article-id><article-id pub-id-type="pmcaid">6330771</article-id><article-id pub-id-type="pmcaiid">6330771</article-id><article-id pub-id-type="pmid">30610772</article-id><article-id pub-id-type="doi">10.3325/cmj.2018.59.298</article-id><article-id pub-id-type="publisher-id">CroatMedJ_0298</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Clinical Science</subject></subj-group></article-categories><title-group><article-title>Liver damage indices as a tool for modifying methadone maintenance treatment: a cross-sectional study</article-title><alt-title alt-title-type="running-head">Klju&#269;evi&#263; et al<bold>:</bold> Liver damage and methadone metabolism in MMT</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Klju&#269;evi&#263;</surname><given-names initials="&#x17D;">&#381;eljko</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Benzon</surname><given-names initials="B">Benjamin</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Klju&#269;evi&#263;</surname><given-names initials="N">Nikola</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ver&#353;i&#263; Bratin&#269;evi&#263;</surname><given-names initials="M">Maja</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sutlovi&#263;</surname><given-names initials="D">Davorka</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><aff id="aff1"><label>1</label>Public Health Institute of Split-Dalmatia County, Split, Croatia</aff><aff id="aff2"><label>2</label>Department of Anatomy, Histology, and Embryology, University of Split School of Medicine, Split, Croatia</aff><aff id="aff3"><label>3</label>Department of Forensic Medicine, University of Split School of Medicine, Split, Croatia</aff><aff id="aff4"><label>4</label>Department of Toxicology and Pharmacogenetics, University of Split School of Medicine, Split, Croatia</aff><aff id="aff5"><label>5</label>Department of Pathology, Forensic Medicine and Cytology, University Hospital Center Split, Split, Croatia</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to:&#8232;&#381;eljko Klju&#269;evi&#263;&#8232;Public Health Institute of Split-Dalmatia County&#8232;Vukovarska 46&#8232;21 000 Split, Croatia&#8232;<italic toggle="yes"><email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="zeljko.kljucevic@gmail.com">zeljko.kljucevic@gmail.com</email></italic></corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2018</year></pub-date><volume>59</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">327483</issue-id><fpage>298</fpage><lpage>306</lpage><history><date date-type="received"><day>03</day><month>8</month><year>2018</year></date><date date-type="accepted"><day>17</day><month>12</month><year>2018</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>12</month><year>2018</year></date></event><event event-type="pmc-live"><date><day>23</day><month>01</month><year>2019</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2019-01-24 00:19:49.717"><day>24</day><month>01</month><year>2019</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2018 by the Croatian Medical Journal. All rights reserved.</copyright-statement><copyright-year>2018</copyright-year><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CroatMedJ_0298.pdf"/><abstract><sec><title>Aim</title><p>To assess the effect of liver damage on methadone metabolism in opiate addicts undergoing methadone maintenance treatment (MMT).</p></sec><sec><title>Methods</title><p>This cross-sectional study recruited 74 patients treated at the outpatient clinic of Public Health Institute of Split-Dalmatia County from 2013-2016. Concentrations of methadone and its main inactive metabolite were measured in participants&#8217; biological samples on regular check-ups. Urine samples obtained before oral methadone intake, and blood and urine samples obtained 90 minutes after methadone intake were analyzed using gas chromatography/mass spectrometry. Participants were divided into groups according to liver damage criteria: hepatitis C virus status (positive, negative, or clinical remission); aspartate aminotransferase to platelet ratio (APRI) index (&lt;0.7 and &#8805;0.7); and fibrosis-4 score (&lt;1.45, 1.45-3.25, &gt;3.25).</p></sec><sec><title>Results</title><p>Metabolic ratio and methadone metabolite concentration in plasma decreased linearly with HCV infection status by the factor of 1.67 (<italic toggle="yes">P</italic>&#8201;=&#8201;0.001) and 2.2 (<italic toggle="yes">P</italic>&#8201;=&#8201;0.043), respectively. Metabolic ratio in plasma decreased in patients with APRI index &#8805;0.7 by the average factor of 2.12 (<italic toggle="yes">P</italic>&#8201;=&#8201;0.01) and methadone metabolite concentration in plasma decreased by the factor of 6.16 (<italic toggle="yes">P</italic>&#8201;=&#8201;0.009). Metabolic ratio in urine decreased with the severity of fibrosis-4 score by the average factor of 1.63 (<italic toggle="yes">P</italic>&#8201;=&#8201;0.008), whereas methadone metabolite concentration decreased by the factor of 3.53 (<italic toggle="yes">P</italic>&#8201;=&#8201;0.007).</p></sec><sec><title>Conclusion</title><p>Liver damage decreases methadone metabolism. Indices of liver function should be calculated regularly during MMT for methadone dose titration.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Methadone maintenance treatment (MMT) is a common treatment approach for patients with opiate addiction (<xref rid="R1" ref-type="bibr">1</xref>). Physicians should individually evaluate the addiction phase and stage, together with psychological and social factors affecting the treatment course (<xref rid="R2" ref-type="bibr">2</xref>). Methadone dose enhancement is mainly based on patient&#8217;s subjective opinion of therapy effectiveness and clinician&#8217;s empirical judgement rather than on objective findings (<xref rid="R3" ref-type="bibr">3</xref>). Individual response to methadone varies because of genetic and proteomic differences as well as common psychological and mental comorbidities (<xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref>) that interfere with methadone metabolism by increasing toxicity and drug side effects (<xref rid="R1" ref-type="bibr">1</xref>). The main dose-dependent adverse effects of chronic methadone use are cardiotoxicity (<xref rid="R1" ref-type="bibr">1</xref>), nephrotoxicity (<xref rid="R6" ref-type="bibr">6</xref>), and behavioral/cognitive disorders (<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref>). Therefore, clinicians should have these toxic effects in mind when optimizing MMT and determining the lowest effective dose for each individual. Furthermore, chronic addiction is a major epidemiological and social problem, especially since frequent comorbidities make the treatment challenging. Promiscuity, unprotected sexual intercourses, and drug injectors sharing (<xref rid="R9" ref-type="bibr">9</xref>) in this population lead to increased transmission of hepatitis C virus (HCV), hepatitis B virus, and human immunodeficiency virus (HIV) and high prevalence of chronic viral infection (<xref rid="R10" ref-type="bibr">10</xref>).</p><p>The liver converts methadone into an inactive metabolite, which is why it is important to monitor the liver physiological capacity during MMT. The liver&#8217;s physiological deficit could increase the amount of unmetabolized methadone and its toxic potential due to the chronic overdose (<xref rid="R11" ref-type="bibr">11</xref>). Although liver biopsy has been the gold standard for the diagnosis and quantification of liver damage (fibrosis), it has several disadvantages (<xref rid="R12" ref-type="bibr">12</xref>-<xref rid="R14" ref-type="bibr">14</xref>). Transient elastography, on the other hand, predicts the severity of hepatic fibrosis but not the liver metabolic capacitance (<xref rid="R15" ref-type="bibr">15</xref>). Cheap and easy-to-obtain alternatives to these approaches for evaluation of liver dysfunction are aspartate aminotransferase (AST) to platelet ratio (APRI) index (<xref rid="R16" ref-type="bibr">16</xref>) and fibrosis 4 (FIB-4) score (<xref rid="R17" ref-type="bibr">17</xref>), both non-invasive fibrosis indices using data from routine biochemical and hematological analyses. These tools have significant sensitivity and specificity and can be applied during each visit (<xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R17" ref-type="bibr">17</xref>). FIB-4 score and APRI index have been used in a variety of models for liver damage prediction (<xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R19" ref-type="bibr">19</xref>).</p><p>Methadone metabolism in opiate addicts undergoing MMT was studied by Wu et al, but only in patients with HCV infection (<xref rid="R10" ref-type="bibr">10</xref>). No study has used APRI and FIB-4 as predictors of liver damage in this group of patients and compared them with HCV infection status. Our aim was to investigate methadone metabolism properties by measuring plasma and urine concentrations of methadone and its most common inactive metabolite, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), and to examine if liver dysfunction influences methadone metabolism. The second aim of our study was to assess whether FIB-4 score and APRI index are useful in evaluating liver damage in patients with heroin addiction undergoing MMT treatment. Our hypothesis was that, due to disrupted liver metabolic capacity, patients with liver dysfunction taking the same initial dose of methadone as the patients with normal liver function would have greater concentration of active methadone in biological samples.</p><sec sec-type="methods"><title>Patients and methods</title><sec><title>Participants and materials</title><p>This cross-sectional study was conducted in the outpatient clinic of Croatian Public Health Institute of Split-Dalmatia County between 2013 and 2016. Adult male patients with heroin addiction undergoing MMT were assessed for eligibility and 74 patients met the inclusion criteria (<xref ref-type="fig" rid="F1">Figure 1</xref>). After 18 (25%) participants were excluded because of low compliance or lack of necessary data from medical records (Supplementary Table 1<xref ref-type="supplementary-material" rid="S1">(supplementary table 1)</xref>), the final sample consisted of 56 participants, who were divided into groups according to their HCV status (positive, negative, or clinical remission [CR]; APRI index (&lt;0.7 and &#8805;0.7); and FIB-4 score (&lt;1.45, 1.45-3.25, &gt;3.25) (<xref ref-type="fig" rid="F1">Figure 1</xref>).</p><fig id="F1" fig-type="figure" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Study flowchart. HIV &#8211; human immunodeficiency virus; HBV &#8211; hepatitis B virus; CR &#8211; clinical remission; APRI &#8211; aspartate transaminase to platelet index, FIB-4 &#8211; Fibrosis-4 score. *For reasons of exclusion please see Supplementary Table 1<xref ref-type="supplementary-material" rid="S1">(supplementary table 1)</xref>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="CroatMedJ_0298-F1.jpg"/></fig><p>The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the University Hospital Split, Croatia (No. 530-01/12-01/164, December 6, 2012). All participants received detailed information and signed a written informed consent for participation and data publication.</p><p>Sample size was determined on the basis of a previous study (<xref rid="R10" ref-type="bibr">10</xref>) and a pilot study, which included 19 adult male opiate addicts aged &#8805;21 years and treated within the outpatient MMT program of the Institute for Public Health of Split-Dalmatia County. Inclusion and exclusion criteria and samples collection were the same as in the present study.</p></sec><sec><title>Methods</title><p>Demographic, clinical, and laboratory assessments were made at the initial meeting with the participants. The data on age, MMT dose (in milligrams), and treatment duration (in months) were obtained from medical records. Height and weight were measured as part of clinical examination, and body mass index (BMI) and weight-based dose were calculated. Interviewer-administered assessment was conducted for each participant. Aspartate aminotransferase (AST, reference range &lt;41 IU/L), alanine transaminase (ALT, reference range &lt;41 IU/L), and platelet count (reference range 150-400&#8201;&#215;&#8201;10<sup>9</sup>/L) were determined from the blood samples analyzed at the University of Split, Department of Pathology and Forensic Medicine.</p><p>HCV status is a widely accepted predictor of liver damage (<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R20" ref-type="bibr">20</xref>). APRI index (<xref rid="R16" ref-type="bibr">16</xref>) and FIB-4 score (<xref rid="R17" ref-type="bibr">17</xref>) were used in our study as non-invasive measures for prediction of liver damage. APRI index &#8805;0.7 had sensitivity of 77% and specificity of 72% for predicting significant hepatic fibrosis (<xref rid="R16" ref-type="bibr">16</xref>). FIB-4 score &lt;1.45 had 90% negative predictive value for the advanced fibrosis, while FIB-4&#8201;&#8805;&#8201;3.25 had 97% specificity and 65% positive predictive value for advanced fibrosis (<xref rid="R17" ref-type="bibr">17</xref>).</p><p>Methadone and EDDP concentrations were determined in biological samples obtained from the participants at their regular check-ups. The recommended therapeutic dose for each individual was previously determined on the basis of their clinical presentation and was not modified for at least last six months. Urine samples were obtained before oral methadone administration, and blood and urine samples were obtained 90 minutes after methadone administration. The samples were stored at 4&#176;C and analyzed within 1-4 days.</p><p>Gas chromatography/mass spectrometry drug analysis was performed using a Shimadzu GC-2010 instrument (Kyoto, Japan) as previously described (<xref rid="R21" ref-type="bibr">21</xref>). Briefly, racemic methadone hydrochloride and EDDP perchlorate were obtained from Lipomed AG (Arlesheim, Switzerland). Sera samples were prepared for analysis using a liquid-liquid extraction method, and 2 mL was added to pre-labeled Toxi Tubes A (Varian, Palo Alto, CA, USA) (<xref rid="R22" ref-type="bibr">22</xref>). The samples were extracted on the rotor and centrifuged. The supernatants were separated in glass test tubes and evaporated under a stream of inert gas of nitrogen to dryness. The dry residue was dissolved in 30 &#956;L chloroform and transferred to a glass vial. Standard methadone and EDDP solutions were used for method validation. After EDDP and methadone plasma and urine concentration levels were measured, metabolic ratio (MR) was calculated as the concentration ratio of EDDP to methadone in urine specimens. The MR is unitless and represents the relationship of methadone to its metabolite at the time of collection (<xref rid="R23" ref-type="bibr">23</xref>).</p></sec><sec><title>Statistical analysis</title><p>MR in urine, and MTD and EDDP concentration in plasma, were log<sub>10</sub>-transformed because the data followed log-normal distribution. If data are log transformed, the difference between means of data logarithms becomes a ratio, which when transformed back to the original scale becomes the ratio of two geometric means (<xref rid="R24" ref-type="bibr">24</xref>,<xref rid="R25" ref-type="bibr">25</xref>). Therefore, the effect sizes in this study are expressed as geometric mean ratios and 95% confidence intervals (CI). Significance of difference between continuous variables was analyzed using <italic toggle="yes">t</italic> test, linear test for trend, and multiple linear regression. Descriptive statistics are expressed as a median and interquartile range for continuous variables or as a percentage for proportions. Explanatory power (R<sup>2</sup>) represents the determination coefficient of linear models, <italic toggle="yes">t</italic> test model, or multiple linear regression. Model selection was performed using the Akaike information criterion (AIC) (<xref rid="R26" ref-type="bibr">26</xref>). The level of significance was set at <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05. Study sample size was determined so that study had 80% power to detect small effect size of Cohen&#8217;s f<sup>2</sup>&#8201;=&#8201;0.15. Statistical analysis was performed using GraphPad Prism 7.02 software for Windows (GraphPad Software, La Jolla, CA, USA), and power calculation was performed using the G*Power software (Heinrich Heine University, Dusseldorf, Germany). Bayesian factors (BF) were calculated by using JASP software (JASP Team 2017, version 0.8.3.1, <italic toggle="yes"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://jasp-stats.org">https://jasp-stats.org</ext-link></italic>).</p></sec></sec><sec sec-type="results"><title>Results</title><p>Twenty-four of 56 participants (43%) were HCV positive (<xref rid="T1" ref-type="table">Table 1</xref>). All participants were treated with a median methadone dose of 80 mg (range: 50-100 mg). Median duration of MMT was 90 months (range: 46-173 months), without any significant difference in dose or treatment duration between HCV-positive and HCV-negative group. APRI index higher than 0.7 was found in 27 (37.5%) participants and FIB-4 higher than 3.25 in 8 (14.28%) participants (<xref rid="T1" ref-type="table">Table 1</xref>). Median age of the entire cohort was 43 years (range: 39-50 years), and there were no significant differences between the groups in BMI or the dose relative to patients&#8217; body weight.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographic and laboratory findings (median and interquartile range) in study participants on methadone maintenance treatment divided according to hepatitis C virus (HCV) infection, aspartate transaminase to platelet ratio index (APRI), and fibrosis-4 score</p></caption><table frame="hsides" rules="groups"><col width="87" span="1"/><col width="49" span="1"/><col width="56" span="1"/><col width="46" span="1"/><col width="45" span="1"/><col width="45" span="1"/><col width="46" span="1"/><col width="46" span="1"/><col width="40" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Parameter</th><th colspan="3" valign="top" align="center" scope="colgroup" rowspan="1">HCV infection</th><th colspan="2" valign="top" align="center" scope="colgroup" rowspan="1">APRI</th><th colspan="3" valign="top" align="center" scope="colgroup" rowspan="1">Fibrosis-4 score</th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">negative (n&#8201;=&#8201;19)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">clinical remission (n&#8201;=&#8201;13)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">positive (n&#8201;=&#8201;24)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">&lt;0.7 (n&#8201;=&#8201;35)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">&#8805;0.7 (n&#8201;=&#8201;21)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">&lt;1.45 (n&#8201;=&#8201;30)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">1.45-3.25 (n&#8201;=&#8201;18)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">&#707;3.25 (n&#8201;=&#8201;8)</th></tr></thead><tbody><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Age (years)</td><td valign="top" align="center" rowspan="1" colspan="1">43 (38-52)</td><td valign="top" align="center" rowspan="1" colspan="1">42 (38-49)</td><td valign="top" align="center" rowspan="1" colspan="1">44 (40-49)</td><td valign="top" align="center" rowspan="1" colspan="1">42 (39-49)</td><td valign="top" align="center" rowspan="1" colspan="1">45 (39-50)</td><td valign="top" align="center" rowspan="1" colspan="1">42 (38-48)</td><td valign="top" align="center" rowspan="1" colspan="1">42 (40-49)</td><td valign="top" align="center" rowspan="1" colspan="1">46 (38-54)</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Treatment duration (months)</td><td valign="top" align="center" rowspan="1" colspan="1">68 (49-224)</td><td valign="top" align="center" rowspan="1" colspan="1">71 (53-168)</td><td valign="top" align="center" rowspan="1" colspan="1">125 (37-162)</td><td valign="top" align="center" rowspan="1" colspan="1">109 (43-179)</td><td valign="top" align="center" rowspan="1" colspan="1">75 (70-150)</td><td valign="top" align="center" rowspan="1" colspan="1">90 (48-179)</td><td valign="top" align="center" rowspan="1" colspan="1">134 (43-187)</td><td valign="top" align="center" rowspan="1" colspan="1">94 (51-145)</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Body mass index (kg/m<sup>2</sup>)</td><td valign="top" align="center" rowspan="1" colspan="1">24.0 (21.4-27.1)</td><td valign="top" align="center" rowspan="1" colspan="1">25.0 (22.7-25.7)</td><td valign="top" align="center" rowspan="1" colspan="1">26.0 (22.8-29.1)</td><td valign="top" align="center" rowspan="1" colspan="1">24.0 (22.8-27.7)</td><td valign="top" align="center" rowspan="1" colspan="1">26.0 (22.2-29.9)</td><td valign="top" align="center" rowspan="1" colspan="1">25.0 (23.3-27.9)</td><td valign="top" align="center" rowspan="1" colspan="1">26.0 (22.8-28.4)</td><td valign="top" align="center" rowspan="1" colspan="1">24.0 (21.1-29.0)</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Dose (mg/kg)</td><td valign="top" align="center" rowspan="1" colspan="1">1.00 (0.58-1.85)</td><td valign="top" align="center" rowspan="1" colspan="1">0.93 (0.38-1.07)</td><td valign="top" align="center" rowspan="1" colspan="1">1.02 (0.67-1.29)</td><td valign="top" align="center" rowspan="1" colspan="1">0.94 (1.25-1.92)</td><td valign="top" align="center" rowspan="1" colspan="1">0.98 (0.59-1.27)</td><td valign="top" align="center" rowspan="1" colspan="1">0.83 (0.55-1.22)</td><td valign="top" align="center" rowspan="1" colspan="1">1.16 (0.83-1.54)</td><td valign="top" align="center" rowspan="1" colspan="1">0.79 (0.37-1.04)</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Aspartate transaminase (U/L)</td><td valign="top" align="center" rowspan="1" colspan="1">32 (21-43)</td><td valign="top" align="center" rowspan="1" colspan="1">27 (21-44)</td><td valign="top" align="center" rowspan="1" colspan="1">68 (42-76)</td><td valign="top" align="center" rowspan="1" colspan="1">30 (22-35)</td><td valign="top" align="center" rowspan="1" colspan="1">92 (65-89)</td><td valign="top" align="center" rowspan="1" colspan="1">31 (21-41)</td><td valign="top" align="center" rowspan="1" colspan="1">43 (32-72)</td><td valign="top" align="center" rowspan="1" colspan="1">150 (83-232)</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Alanine aminotransferase (U/L)</td><td valign="top" align="center" rowspan="1" colspan="1">23 (17-74)</td><td valign="top" align="center" rowspan="1" colspan="1">20 (15-53)</td><td valign="top" align="center" rowspan="1" colspan="1">91 (32-102)</td><td valign="top" align="center" rowspan="1" colspan="1">22 (155-32)</td><td valign="top" align="center" rowspan="1" colspan="1">120 (54-177)</td><td valign="top" align="center" rowspan="1" colspan="1">24 (17-65)</td><td valign="top" align="center" rowspan="1" colspan="1">43 (23-92)</td><td valign="top" align="center" rowspan="1" colspan="1">98 (81-144)</td></tr></tbody></table></table-wrap><sec><title>Chronic HCV infection and methadone metabolism</title><p>MR in urine after methadone administration decreased linearly with HCV infection status by the average factor of 1.67 (95% CI 1.24 to 2.24, <italic toggle="yes">P</italic>&#8201;=&#8201;0.001; <xref ref-type="fig" rid="F2">Figure 2A</xref>). A similar trend was observed before methadone administration, but the difference was not significant (fold-change in geometric mean ratio&#8201;=&#8201;1.17, 95% CI 0.058-1.08, <italic toggle="yes">P</italic>&#8201;=&#8201;0.153, BF&#8201;=&#8201;0.7; <xref ref-type="fig" rid="F2">Figure 2B</xref>). There were no differences in methadone plasma concentration in patients with different HCV infection status (<xref ref-type="fig" rid="F2">Figure 2C</xref>). Plasma EDDP after methadone ingestion decreased with the HCV infection status by the average factor of 2.2 (95% CI 1.03-4.74, <italic toggle="yes">P</italic>&#8201;=&#8201;0.043) (<xref ref-type="fig" rid="F2">Figure 2D</xref>).</p><fig id="F2" fig-type="figure" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Methadone (MTD) pharmacokinetics stratified by hepatitis C virus (HCV) infection status. (<bold>A</bold>) A significant decrease in MR in urine samples after methadone administration (&#946;&#8201;=&#8201;-0.2215, 95% CI 1.24 to 2.24, <italic toggle="yes">P</italic>&#8201;=&#8201;0.001). (<bold>B</bold>) A non-significant difference in logarithmically transformed metabolic ratio (MR) in urine samples before methadone administration (&#946;&#8201;=&#8201;-0.0994, 95% confidence interval [CI] 0.058 to 1.08, <italic toggle="yes">P</italic>&#8201;=&#8201;0.153, BF&#8201;=&#8201;0.7). (<bold>C</bold>) A non-significant difference in logarithmically transformed methadone plasma concentration (&#946;&#8201;=&#8201;0.0275, 95% CI -0.2481 to 0.3032, <italic toggle="yes">P</italic>&#8201;=&#8201;0.841, BF&#8201;=&#8201;0.27). (<bold>D</bold>) A significant difference in logarithmically transformed plasma concentration of 1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) (&#946;&#8201;=&#8201;-0.3436, 95% CI 1.03 to 4.74, <italic toggle="yes">P</italic>&#8201;=&#8201;0.043). &#946; &#8211; slope parameter of log linear model, BF &#8211; Bayesian factor.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="CroatMedJ_0298-F2.jpg"/></fig></sec><sec><title>APRI index and methadone metabolism</title><p>MR in urine after methadone administration decreased in participants with APRI index &#8805;0.7 by the average factor of 2.12 (95% CI 1.2- 3.74, <italic toggle="yes">P</italic>&#8201;=&#8201;0.010) compared with patients with APRI index &lt;0.7 (<xref ref-type="fig" rid="F3">Figure 3A</xref>). Although a similar trend was observed before methadone administration (1.52, 95% CI 0.85-2.68, <italic toggle="yes">P</italic>&#8201;=&#8201;0.154, BF&#8201;=&#8201;0.65), the difference was not significant (<xref ref-type="fig" rid="F3">Figure 3B</xref>). Methadone plasma concentration non-significantly increased in participants with APRI index &#8805;0.7 (geometric mean ratio 0.572, 95% CI 0.179 to 1.819, <italic toggle="yes">P</italic>&#8201;=&#8201;0.338, BF&#8201;=&#8201;0.4) (<xref ref-type="fig" rid="F3">Figure 3C</xref>). Plasma EDDP concentration in patients with APRI index &#8805;0.7 significantly decreased by the average factor of 6.16 (95% C1.57-24, <italic toggle="yes">P</italic>&#8201;=&#8201;0.009) (<xref ref-type="fig" rid="F3">Figure 3D</xref>).</p><fig id="F3" fig-type="figure" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Methadone (MTD) pharmacokinetics stratified by aspartate transaminase to platelet ratio (APRI) index. A significant decrease in logarithmically transformed metabolic ratio (MR) in urine samples in patients with APRI index &#8805;7 compared with those with APRI index &lt;0.7 after methadone administration (95% confidence interval [CI] 0.12 to 3.74, <italic toggle="yes">P</italic>&#8201;=&#8201;0.010). (<bold>A</bold>). A non-significant difference in MR before methadone administration (95% CI 0.85 to 2.68, <italic toggle="yes">P</italic>&#8201;=&#8201;0.154, BF&#8201;=&#8201;0.65) <bold>(B)</bold> A non-significant difference in logarithmically transformed methadone plasma concentration according to APRI status (95% CI 0.179 to 1.819, <italic toggle="yes">P</italic>&#8201;=&#8201;0.338, BF&#8201;=&#8201;0.4). (<bold>C</bold>) A significant difference in logarithmically transformed plasma 1,5-dimethyl-3,3-diphenylpyrrolidine metabolite (EDDP) (95% CI 57 to 24, <italic toggle="yes">P</italic>&#8201;=&#8201;0.009). (<bold>D</bold>) BF &#8211; Bayesian factor.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="CroatMedJ_0298-F3.jpg"/></fig></sec><sec><title>FIB-4 score and methadone metabolism</title><p>MR before and after oral methadone intake decreased with the severity of FIB-4 score by the average factor of 1.57 (95% CI 1.08 to 2.27, <italic toggle="yes">P</italic>&#8201;=&#8201;0.018) and 1.63 (95% CI 1.15 to 2.44, <italic toggle="yes">P</italic>&#8201;=&#8201;0.008), respectively (<xref ref-type="fig" rid="F4">Figure 4A and 4B</xref>). Methadone plasma concentration was not associated with the severity of FIB-4 score (<xref ref-type="fig" rid="F4">Figure 4C</xref>), whereas plasma EDDP concentration decreased with increasing FIB-4 score by the factor of 3.53 (95% CI 1.43 to 8.72, <italic toggle="yes">P</italic>&#8201;=&#8201;0.007) (<xref ref-type="fig" rid="F4">Figure 4D</xref>).</p><fig id="F4" fig-type="figure" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Methadone (MTD) pharmacokinetics stratified according to fibrosis-4 (FIB-4) score. A significant decrease in logarithmically transformed metabolic ratio (MR) with rising FIB-4 score before (&#946;&#8201;=&#8201;-0.3567, 95% confidence interval [CI] 1.08 to 2.27, <italic toggle="yes">P</italic>&#8201;=&#8201;0.018) (<bold>A</bold>) and after methadone administration (&#946;&#8201;=&#8201;-0.2236, 95% CI 1.15 to 2.44, <italic toggle="yes">P</italic>&#8201;=&#8201;0.008) (<bold>B</bold>). A non-significant difference in logarithmically transformed plasma methadone concentration according to FIB-4 score (&#946;&#8201;=&#8201;-0.0543, <italic toggle="yes">P</italic>&#8201;=&#8201;0.749, BF&#8201;=&#8201;0.28) (<bold>C</bold>). A significant decrease in plasma 1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) in patients with high FIB-4 score (&#946;&#8201;=&#8201;-0.5478, 95% CI&#8201;=&#8201;1.43 to 8.72, <italic toggle="yes">P</italic>&#8201;=&#8201;0.007) (<bold>D</bold>). &#946; &#8211; slope parameter of log linear model, BF &#8211; Bayesian factor.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="CroatMedJ_0298-F4.jpg"/></fig></sec><sec><title>Comparison of liver damage indices</title><p>To determine which of the liver damage indices better explains changes in methadone metabolism (<xref rid="T2" ref-type="table">Table 2</xref>), we compared them in terms of explanatory power (R<sup>2</sup>) for differences in methadone and EDDP plasma concentration and MR in urine. Overall, the best explanatory power was shown by FIB-4 score. R<sup>2</sup> for stratification of methadone plasma concentration of FIB-4 was two times higher than that for APRI and 6 times higher than that for HCV infection status. For EDDP plasma concentration, non-invasive fibrosis indices offered better explanatory power than the HCV infection status (<xref rid="T2" ref-type="table">Table 2</xref>). For MR determination in urine, the best stratification variable was HCV infection status, although the explanatory power of all liver damage indices remained rather low. All three predictors better explained differences in urine MR and plasma EDDP than plasma methadone. The optimal model for predicting methadone metabolism based on HCV, FIB4, and other demographic and morphometric characteristics of our participants (Supplementary Table 2<xref ref-type="supplementary-material" rid="S2">(supplementary table 2)</xref>) predicted log of MR after methadone intake based on HCV status, FIB-4, and participant age, with an explanatory power of 27% (Supplementary Table 3<xref ref-type="supplementary-material" rid="S3">(supplementary table 3)</xref>).</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Explanatory power (R<sup>2</sup>) of stratification variables of liver damage predictors including hepatitis C virus (HCV) infection status, aspartate transaminase to platelet ratio index (APRI), and fibrosis-4 score for difference in plasma methadone, plasma 2- ethylidene-1,5-dimethyl-3,3-diphenylpyrroldine (EDDP), and urine metabolic ratio</p></caption><table frame="hsides" rules="groups"><col width="122" span="1"/><col width="113" span="1"/><col width="111" span="1"/><col width="117" span="1"/><thead><tr><th rowspan="2" valign="top" align="center" scope="col" colspan="1">Main outcome measures</th><th colspan="3" valign="top" align="center" scope="colgroup" rowspan="1">Stratification variables</th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1">HCV status</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">APRI</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">fibrosis-4 score</th></tr></thead><tbody><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><bold>Plasma methadone (mg/L, %)</bold></td><td valign="top" align="center" rowspan="1" colspan="1">0.7</td><td valign="top" align="center" rowspan="1" colspan="1">2.1</td><td valign="top" align="center" rowspan="1" colspan="1">4.2</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><bold>Plasma EDDP (mg/L, %)</bold></td><td valign="top" align="center" rowspan="1" colspan="1">7.3</td><td valign="top" align="center" rowspan="1" colspan="1">11.7</td><td valign="top" align="center" rowspan="1" colspan="1">12.6</td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1"><bold>Urine metabolic ratio (%)</bold></td><td valign="top" align="center" rowspan="1" colspan="1">17.7</td><td valign="top" align="center" rowspan="1" colspan="1">11.6</td><td valign="top" align="center" rowspan="1" colspan="1">13.9</td></tr></tbody></table></table-wrap></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>We found a significant association between non-invasive predictors of liver damage and a decrease in urine and plasma EDDP concentration, probably due to impaired liver methadone metabolism. MR changes could be attributed to lower overall EDDP concentration rather than higher methadone concentration, which indicates diminished liver capacity for methadone processing.</p><p>There was no difference in plasma methadone levels between participants with different HCV infection status, FIB-4 score, or APRI index. This could be explained by methadone&#8217;s lipophilic properties and high volume of distribution (<xref rid="R27" ref-type="bibr">27</xref>). Methadone concentration in tissues is higher than in plasma, with only about 2% of absorbed methadone remaining in the plasma compartment (<xref rid="R27" ref-type="bibr">27</xref>). Therefore, it is understandable that we could not find a difference in the plasma methadone concentration between the groups; plasma methadone represents a small fraction of the total methadone concentration following oral administration.</p><p>Our results do not confirm previous findings (<xref rid="R20" ref-type="bibr">20</xref>) of higher initial methadone doses in HCV-positive patients. In our study, the initial methadone dose was around 1 mg/kg regardless of BMI, treatment duration, HCV infection status, or participant&#8217;s age and did not differ between the groups. However, it seems that this dose if orally administered does not provide the same drug amount or concentration to all patients. This could be explained by different pharmacokinetic profiles in patients with APRI&#8805;0.7 index and FIB-4 score &gt;3.25, hence depending on an individual hepatic capacity for methadone metabolism.</p><p>Although MR in urine, as an overall measure of methadone metabolic capacity, and EDDP plasma concentration decreased linearly with HCV infection status, we did not observe any differences in methadone plasma concentration. These findings differ from the findings by Wu et al (<xref rid="R10" ref-type="bibr">10</xref>), who reported higher plasma methadone concentration in patients with HCV infection, together with lower MR. These discrepancies may be attributed to differences in race, sample size, or inclusion criteria. Unlike Wu et al (<xref rid="R10" ref-type="bibr">10</xref>), we divided the participants according to HCV status, distinguishing HCV-positive from those in remission and excluded patients co-infected with hepatitis B virus or HIV. Finally, the difference could be attributed to the surprisingly high rate of around 95% HCV-positive patients in the study by Wu et al (<xref rid="R10" ref-type="bibr">10</xref>), compared with 43% in our study.</p><p>Furthermore, in our study, patients with APRI index &#8805;0.7 and FIB-4 score 1.45-3.25 and &gt;3.25 had decreased MR in urine and EDDP plasma concentration. Although there are several reports on the usefulness of FIB-4 score and APRI index in a variety of models for liver damage prediction (<xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R19" ref-type="bibr">19</xref>), this is, to the best of our knowledge, the first report evaluating the use of FIB-4 score and APRI index in methadone metabolism prediction and dose modification in heroin abusers undergoing MMT treatment.</p><p>The best explanatory power was obtained by FIB-4 score. APRI index had three times higher explanatory power for plasma methadone when compared with HCV infection status. These results suggest that indices of liver fibrosis better assess methadone metabolism in patients undergoing MMT than clinical diagnosis of HCV infection status.</p><p>One of the study limitations is the small sample size, but the poor compliance and motivation of these patients should be taken into consideration when conducting this type of studies. Another limitation is the lack of female participants, who were not recruited due to small number of women treated at our institution. Blood samples before methadone administration were not collected because IV drug users often suffer from damaged blood vessels, which makes the sampling difficult and sometimes impossible. Furthermore, the blood methadone concentration reaches the peak value of 2.5 about 4 h after therapeutic dose administration, during which time participants become less compliant (<xref rid="R28" ref-type="bibr">28</xref>). These blood samples could have provided more information on liver metabolic capacity and methadone body elimination. Additionally, this study did not consider genetic influence of CYP3A4 and CYP2B6 and molecular properties of methadone elimination, which is an issue that merits further study.</p><p>In conclusion, this is the first study evaluating the use of APRI index and FIB-4 score in methadone metabolism prediction and comparing these indices with HCV infection status. Liver fibrosis indices and HCV status were to a lesser extent associated with decreased methadone liver-mediated metabolism in patients with heroin addiction suitable for MMT program. Therefore, calculation of these indices could be a potential tool for clinicians in everyday practice. Future research should assess the correlation between the mentioned variables and methadone-dosing regimen to determine whether these variables may be used to titrate methadone target doses in patients starting methadone maintenance program.</p></sec></body><back><ack><p>Oxford Centre for Evidence-based Medicine level of evidence: 2b.</p><p>Funding The financial expenses of this study were covered by the annual grant for researcher excellence received by DS from the University of Split School of Medicine, and from &#381;K's PhD school tuition fee.</p><p>Ethical approval received from the Ethics Committee of the University Hospital Split, Croatia (No. 530-01/12-01/164, December 6, 2012).</p><p>Declaration of authorship &#381;K-and DS conceived and designed the study, and acquired the data. All authors analyzed and interpreted the data; drafted the manuscript; critically revised the manuscript for important intellectual content; gave approval of the version to be submitted; agree to be accountable for all aspects of the work.</p><p>Competing interests All authors have completed the Unified Competing Interest form at <italic toggle="yes"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.icmje.org/coi_disclosure.pdf">www.icmje.org/coi_disclosure.pdf</ext-link></italic> (available on request from the corresponding author) and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.</p></ack><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alinejad</surname><given-names>S</given-names></name><name name-style="western"><surname>Kazemi</surname><given-names>T</given-names></name><name name-style="western"><surname>Zamani</surname><given-names>N</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>RS</given-names></name><name name-style="western"><surname>Mehrpour</surname><given-names>O</given-names></name></person-group><article-title>A systematic review of the cardiotoxicity of methadone.</article-title><source>EXCLI J</source><year>2015</year><volume>14</volume><fpage>577</fpage><lpage>600</lpage><pub-id pub-id-type="pmid">26869865</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.17179/excli2015-553</pub-id><pub-id pub-id-type="pmcid">PMC4747000</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ayanga</surname><given-names>D</given-names></name><name name-style="western"><surname>Shorter</surname><given-names>D</given-names></name><name name-style="western"><surname>Kosten</surname><given-names>TR</given-names></name></person-group><article-title>Update on pharmacotherapy for treatment of opioid use disorder.</article-title><source>Expert Opin Pharmacother</source><year>2016</year><volume>17</volume><fpage>2307</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1080/14656566.2016.1244529</pub-id><pub-id pub-id-type="pmid">27734745</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fareed</surname><given-names>A</given-names></name><name name-style="western"><surname>Casarella</surname><given-names>J</given-names></name><name name-style="western"><surname>Amar</surname><given-names>R</given-names></name><name name-style="western"><surname>Vayalapalli</surname><given-names>S</given-names></name><name name-style="western"><surname>Drexler</surname><given-names>K</given-names></name></person-group><article-title>Methadone maintenance dosing guideline for opioid dependence, a literature review.</article-title><source>J Addict Dis</source><year>2010</year><volume>29</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1080/10550880903436010</pub-id><pub-id pub-id-type="pmid">20390694</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naji</surname><given-names>L</given-names></name><name name-style="western"><surname>Dennis</surname><given-names>BB</given-names></name><name name-style="western"><surname>Bawor</surname><given-names>M</given-names></name><name name-style="western"><surname>Varenbut</surname><given-names>M</given-names></name><name name-style="western"><surname>Daiter</surname><given-names>J</given-names></name><name name-style="western"><surname>Plater</surname><given-names>C</given-names></name><etal/></person-group><article-title>The association between age of onset of opioid use and comorbidity among opioid dependent patients receiving methadone maintenance therapy.</article-title><source>Addict Sci Clin Pract</source><year>2017</year><volume>12</volume><fpage>9</fpage><pub-id pub-id-type="doi">10.1186/s13722-017-0074-0</pub-id><pub-id pub-id-type="pmid">28347350</pub-id><pub-id pub-id-type="pmcid">PMC5369183</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teoh Bing Fei</surname><given-names>J</given-names></name><name name-style="western"><surname>Yee</surname><given-names>A</given-names></name><name name-style="western"><surname>Habil</surname><given-names>MH</given-names></name></person-group><article-title>Psychiatric comorbidity among patients on methadone maintenance therapy and its influence on quality of life.</article-title><source>Am J Addict</source><year>2016</year><volume>25</volume><fpage>49</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1111/ajad.12317</pub-id><pub-id pub-id-type="pmid">26692463</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alinejad</surname><given-names>S</given-names></name><name name-style="western"><surname>Ghaemi</surname><given-names>K</given-names></name><name name-style="western"><surname>Abdollahi</surname><given-names>M</given-names></name><name name-style="western"><surname>Mehrpour</surname><given-names>O</given-names></name></person-group><article-title>Nephrotoxicity of methadone: a systematic review.</article-title><source>Springerplus</source><year>2016</year><volume>5</volume><fpage>2087</fpage><pub-id pub-id-type="doi">10.1186/s40064-016-3757-1</pub-id><pub-id pub-id-type="pmid">28018795</pub-id><pub-id pub-id-type="pmcid">PMC5148752</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazhari</surname><given-names>S</given-names></name><name name-style="western"><surname>Keshvari</surname><given-names>Z</given-names></name><name name-style="western"><surname>Sabahi</surname><given-names>A</given-names></name><name name-style="western"><surname>Mottaghian</surname><given-names>S</given-names></name></person-group><article-title>Assessment of Cognitive Functions in Methadone Maintenance Patients.</article-title><source>Addict Health</source><year>2015</year><volume>&#8226;&#8226;&#8226;</volume><fpage>109</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">26885347</pub-id><pub-id pub-id-type="pmcid">PMC4741231</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rass</surname><given-names>O</given-names></name><name name-style="western"><surname>Kleykamp</surname><given-names>BA</given-names></name><name name-style="western"><surname>Vandrey</surname><given-names>RG</given-names></name><name name-style="western"><surname>Bigelow</surname><given-names>GE</given-names></name><name name-style="western"><surname>Leoutsakos</surname><given-names>JM</given-names></name><name name-style="western"><surname>Stitzer</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Cognitive performance in methadone maintenance patients: effects of time relative to dosing and maintenance dose level.</article-title><source>Exp Clin Psychopharmacol</source><year>2014</year><volume>22</volume><fpage>248</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1037/a0035712</pub-id><pub-id pub-id-type="pmid">24548244</pub-id><pub-id pub-id-type="pmcid">PMC4041803</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacob</surname><given-names>SA</given-names></name><name name-style="western"><surname>Mohammed</surname><given-names>F</given-names></name><name name-style="western"><surname>Hassali</surname><given-names>MA</given-names></name></person-group><article-title>Profile of clients attending a methadone clinic.</article-title><source>Malays J Med Sci</source><year>2015</year><volume>22</volume><fpage>58</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">25892951</pub-id><pub-id pub-id-type="pmcid">PMC4390775</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>SL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>SC</given-names></name><name name-style="western"><surname>Tsou</surname><given-names>HH</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>HW</given-names></name><name name-style="western"><surname>Ho</surname><given-names>IK</given-names></name><name name-style="western"><surname>Liu</surname><given-names>SW</given-names></name><etal/></person-group><article-title>Hepatitis C virus infection influences the S-methadone metabolite plasma concentration.</article-title><source>PLoS One</source><year>2013</year><volume>&#8226;&#8226;&#8226;</volume><elocation-id>e69310</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0069310</pub-id><pub-id pub-id-type="pmid">23935979</pub-id><pub-id pub-id-type="pmcid">PMC3720619</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sutlovic</surname><given-names>D</given-names></name><name name-style="western"><surname>Kljucevic</surname><given-names>Z</given-names></name><name name-style="western"><surname>Sliskovic</surname><given-names>L</given-names></name><name name-style="western"><surname>Susnjar</surname><given-names>H</given-names></name><name name-style="western"><surname>Viskovic</surname><given-names>I</given-names></name><name name-style="western"><surname>Definis-Gojanovic</surname><given-names>M</given-names></name></person-group><article-title>Methadone maintenance treatment: a 15-year retrospective study in Split-Dalmatia County, Croatia.</article-title><source>Ther Drug Monit</source><year>2018</year><volume>40</volume><fpage>486</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1097/FTD.0000000000000519</pub-id><pub-id pub-id-type="pmid">29649094</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berenguer</surname><given-names>J</given-names></name><name name-style="western"><surname>Zamora</surname><given-names>FX</given-names></name><name name-style="western"><surname>Aldamiz-Echevarria</surname><given-names>T</given-names></name><name name-style="western"><surname>Von Wichmann</surname><given-names>MA</given-names></name><name name-style="western"><surname>Crespo</surname><given-names>M</given-names></name><name name-style="western"><surname>Lopez-Aldeguer</surname><given-names>J</given-names></name><etal/></person-group><article-title>Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus.</article-title><source>Clin Infect Dis</source><year>2015</year><volume>60</volume><fpage>950</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/cid/ciu939</pub-id><pub-id pub-id-type="pmid">25422386</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Ren</surname><given-names>X</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name></person-group><article-title>Evaluation of APRI and FIB-4 for noninvasive assessment of significant fibrosis and cirrhosis in HBeAg-negative CHB patients with ALT &lt;/= 2 ULN: a retrospective cohort study.</article-title><source>Medicine (Baltimore)</source><year>2017</year><volume>96</volume><elocation-id>e6336</elocation-id><pub-id pub-id-type="doi">10.1097/MD.0000000000006336</pub-id><pub-id pub-id-type="pmid">28328813</pub-id><pub-id pub-id-type="pmcid">PMC5371450</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name></person-group><article-title>The diagnostic value of the FIB-4 index for staging hepatitis B-related fibrosis: a meta-analysis.</article-title><source>PLoS One</source><year>2014</year><volume>&#8226;&#8226;&#8226;</volume><elocation-id>e105728</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0105728</pub-id><pub-id pub-id-type="pmid">25165830</pub-id><pub-id pub-id-type="pmcid">PMC4148327</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perez-Latorre</surname><given-names>L</given-names></name><name name-style="western"><surname>Rivero-Juarez</surname><given-names>A</given-names></name><name name-style="western"><surname>Hontanon</surname><given-names>V</given-names></name><name name-style="western"><surname>Diez</surname><given-names>C</given-names></name><name name-style="western"><surname>Cuenca</surname><given-names>F</given-names></name><name name-style="western"><surname>Martin-Carbonero</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Prognostic value of transient elastography in human immunodeficiency virus-infected patients with chronic hepatitis C.</article-title><source>Open Forum Infect Dis</source><year>2016</year><volume>3</volume><elocation-id>ofw212</elocation-id><pub-id pub-id-type="doi">10.1093/ofid/ofw212</pub-id><pub-id pub-id-type="pmid">27833930</pub-id><pub-id pub-id-type="pmcid">PMC5102143</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>ZH</given-names></name><name name-style="western"><surname>Xin</surname><given-names>YN</given-names></name><name name-style="western"><surname>Dong</surname><given-names>QJ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>XJ</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis.</article-title><source>Hepatology</source><year>2011</year><volume>53</volume><fpage>726</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1002/hep.24105</pub-id><pub-id pub-id-type="pmid">21319189</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sterling</surname><given-names>RK</given-names></name><name name-style="western"><surname>Lissen</surname><given-names>E</given-names></name><name name-style="western"><surname>Clumeck</surname><given-names>N</given-names></name><name name-style="western"><surname>Sola</surname><given-names>R</given-names></name><name name-style="western"><surname>Correa</surname><given-names>MC</given-names></name><name name-style="western"><surname>Montaner</surname><given-names>J</given-names></name><etal/></person-group><article-title>Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.</article-title><source>Hepatology</source><year>2006</year><volume>43</volume><fpage>1317</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1002/hep.21178</pub-id><pub-id pub-id-type="pmid">16729309</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mouly</surname><given-names>S</given-names></name><name name-style="western"><surname>Bloch</surname><given-names>V</given-names></name><name name-style="western"><surname>Peoc&#8217;h</surname><given-names>K</given-names></name><name name-style="western"><surname>Houze</surname><given-names>P</given-names></name><name name-style="western"><surname>Labat</surname><given-names>L</given-names></name><name name-style="western"><surname>Ksouda</surname><given-names>K</given-names></name><etal/></person-group><article-title>Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity.</article-title><source>Br J Clin Pharmacol</source><year>2015</year><volume>79</volume><fpage>967</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1111/bcp.12576</pub-id><pub-id pub-id-type="pmid">25556837</pub-id><pub-id pub-id-type="pmcid">PMC4456129</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>CC</given-names></name><name name-style="western"><surname>Liu</surname><given-names>CH</given-names></name><name name-style="western"><surname>Lin</surname><given-names>CL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>PC</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>TC</given-names></name><name name-style="western"><surname>Lin</surname><given-names>HH</given-names></name><etal/></person-group><article-title>Fibrosis index based on four factors better predicts advanced fibrosis or cirrhosis than aspartate aminotransferase/platelet ratio index in chronic hepatitis C patients.</article-title><source>J Formos Med Assoc</source><year>2015</year><volume>114</volume><fpage>923</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.jfma.2015.07.004</pub-id><pub-id pub-id-type="pmid">26279173</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roncero</surname><given-names>C</given-names></name><name name-style="western"><surname>Fuster</surname><given-names>D</given-names></name><name name-style="western"><surname>Palma-Alvarez</surname><given-names>RF</given-names></name><name name-style="western"><surname>Rodriguez-Cintas</surname><given-names>L</given-names></name><name name-style="western"><surname>Martinez-Luna</surname><given-names>N</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>FJ</given-names></name></person-group><article-title>HIV and HCV infection among opiate-dependent patients and methadone doses: the PROTEUS study.</article-title><source>AIDS Care</source><year>2017</year><volume>29</volume><fpage>1551</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">28393548</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/09540121.2017.1313384</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nestic</surname><given-names>M</given-names></name><name name-style="western"><surname>Babic</surname><given-names>S</given-names></name><name name-style="western"><surname>Pavlovic</surname><given-names>DM</given-names></name><name name-style="western"><surname>Sutlovic</surname><given-names>D</given-names></name></person-group><article-title>Molecularly imprinted solid phase extraction for simultaneous determination of Delta9-tetrahydrocannabinol and its main metabolites by gas chromatography-mass spectrometry in urine samples.</article-title><source>Forensic Sci Int</source><year>2013</year><volume>231</volume><fpage>317</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.forsciint.2013.06.009</pub-id><pub-id pub-id-type="pmid">23890655</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ver&#353;i&#263; Bratin&#269;evi&#263;</surname><given-names>M</given-names></name><name name-style="western"><surname>Viskovi&#263;</surname><given-names>T</given-names></name><name name-style="western"><surname>Sutlovi&#263;</surname><given-names>D</given-names></name></person-group><article-title>Comparison of the solid phase and liquid-liquid extraction methods for methadone determination in human serum and whole blood samples using gas chromatography/mass spectrometry.</article-title><source>Arh Hig Rada Toksikol</source><year>2017</year><volume>68</volume><fpage>308</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1515/aiht-2017-68-2953</pub-id><pub-id pub-id-type="pmid">29337687</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leimanis</surname><given-names>E</given-names></name><name name-style="western"><surname>Best</surname><given-names>BM</given-names></name><name name-style="western"><surname>Atayee</surname><given-names>RS</given-names></name><name name-style="western"><surname>Pesce</surname><given-names>AJ</given-names></name></person-group><article-title>Evaluating the relationship of methadone concentrations and EDDP formation in chronic pain patients.</article-title><source>J Anal Toxicol</source><year>2012</year><volume>36</volume><fpage>239</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1093/jat/bks020</pub-id><pub-id pub-id-type="pmid">22511698</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bland</surname><given-names>JM</given-names></name><name name-style="western"><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>Statistics notes. Logarithms.</article-title><source>BMJ</source><year>1996</year><volume>312</volume><fpage>700</fpage><pub-id pub-id-type="doi">10.1136/bmj.312.7032.700</pub-id><pub-id pub-id-type="pmid">8597743</pub-id><pub-id pub-id-type="pmcid">PMC2350526</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bland</surname><given-names>JM</given-names></name><name name-style="western"><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>Transformations, means, and confidence intervals.</article-title><source>BMJ</source><year>1996</year><volume>312</volume><fpage>1079</fpage><pub-id pub-id-type="doi">10.1136/bmj.312.7038.1079</pub-id><pub-id pub-id-type="pmid">8616417</pub-id><pub-id pub-id-type="pmcid">PMC2350916</pub-id></element-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="book">Anderson DG. Model based inference in the life sciences: a primer on evidence, 1st ed. New York: Springer; 2008.</mixed-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferrari</surname><given-names>A</given-names></name><name name-style="western"><surname>Coccia</surname><given-names>CP</given-names></name><name name-style="western"><surname>Bertolini</surname><given-names>A</given-names></name><name name-style="western"><surname>Sternieri</surname><given-names>E</given-names></name></person-group><article-title>Methadone&#8211;metabolism, pharmacokinetics and interactions.</article-title><source>Pharmacol Res</source><year>2004</year><volume>50</volume><fpage>551</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2004.05.002</pub-id><pub-id pub-id-type="pmid">15501692</pub-id></element-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="book">Sakoman S. Opiate addicts treatment. Zagreb: Clinical Hospital Sestre Milosrdnice; 2012.</mixed-citation></ref></ref-list><sec sec-type="supplementary-material"><title>Additional Material</title><supplementary-material content-type="local-data" id="S1" position="float" orientation="portrait"><caption><title>Supplementary Table 1</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" mimetype="application" mime-subtype="pdf" xlink:href="CroatMedJ_59_s001.pdf" orientation="portrait" id="d35e2039" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="S2" position="float" orientation="portrait"><caption><title>Supplementary Table 2</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" mimetype="application" mime-subtype="pdf" xlink:href="CroatMedJ_59_s002.pdf" orientation="portrait" id="d35e2044" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="S3" position="float" orientation="portrait"><caption><title>Supplementary Table 3</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" mimetype="application" mime-subtype="pdf" xlink:href="CroatMedJ_59_s003.pdf" orientation="portrait" id="d35e2049" position="anchor"/></supplementary-material></sec></back></article></pmc-articleset>